Literature DB >> 8824960

Periodic illness associated with Epstein-Barr virus infection.

J A Lekstrom-Himes1, J K Dale, D W Kingma, P S Diaz, E S Jaffe, S E Straus.   

Abstract

A 15-year-old boy with a 13-year history of periodic fevers, lymphadenopathy, and leukocytosis showed virological, serological, immunohistologic, and molecular evidence of persistent, active, Epstein-Barr virus (EBV) infection. Acyclovir and several other agents failed to alter his clinical course. Comprehensive immunological studies could not identify a defined immune deficiency syndrome to explain the persistent infection, although he does continue to have circulating polymeric EBV-specific immunoglobulin type A, as is seen in individuals during acute EBV infections. In vitro work suggests that this polymeric antibody prevents B cell infection by EBV. Cumulative data suggest that this patient suffers from a novel form of EBV infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8824960     DOI: 10.1093/clinids/22.1.22

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

Review 1.  Signaling activities of gammaherpesvirus membrane proteins.

Authors:  B Damania; J K Choi; J U Jung
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Periodic Illness Associated With Epstein-Barr Virus: A New Diagnosis After a 22-Year Follow-up.

Authors:  Lesia K Dropulic; Mir A Ali; Amanda K Ombrello; Jeffrey I Cohen
Journal:  Clin Infect Dis       Date:  2016-03-29       Impact factor: 9.079

Review 3.  Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification.

Authors:  Hyun-Jung Kim; Young Hyeh Ko; Ji Eun Kim; Seung-Sook Lee; Hyekyung Lee; Gyeongsin Park; Jin Ho Paik; Hee Jeong Cha; Yoo-Duk Choi; Jae Ho Han; Jooryung Huh
Journal:  J Pathol Transl Med       Date:  2017-06-05

Review 4.  Recurrent Fever in Children.

Authors:  Sofia Torreggiani; Giovanni Filocamo; Susanna Esposito
Journal:  Int J Mol Sci       Date:  2016-03-25       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.